Business news and discussion on TalkFuse.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reported late-stage trial results showing that Wegovy substantially reduced BMI in children aged 6 to under 12 with obesity. The findings could help address a treatment gap for younger children, who currently have no approved obesity medicines, although the study does not show whether early treatment changes health outcomes over the long term.
The 167 participants also received dietary and physical activity support. After 68 weeks, BMI fell by 17.4% among children taking Wegovy and rose by 2.2% with placebo among those who stayed on treatment; across all participants, the estimated difference was 16.2 percentage points. More than 40% of treated children no longer met the definition of obesity, and Novo reported no growth or puberty-related safety concerns, but questions remain about treatment and maintenance as children grow up.
In short
- Wegovy lowered BMI in a trial of children aged 6 to under 12.
- More than 40% of treated children no longer had obesity after 68 weeks.
- Long-term effects and treatment as children grow up remain uncertain.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
The results suggest Wegovy could offer a meaningful treatment option for younger children with obesity, for whom no medicines are currently approved. Alongside lifestyle support, reducing BMI may help address a significant treatment gap, and the trial reported no growth or puberty-related safety concerns during the study.
The case against
A substantial BMI reduction over 68 weeks does not establish that treating children this young improves their long-term health or wellbeing. The effects of prolonged use, maintaining weight loss as children grow, and potential risks beyond the trial period remain uncertain, so some may favour caution until more evidence is available.
Explained simply
Obesity in children is assessed using body mass index (BMI), which relates a person’s weight to their height and is interpreted against age and sex. It can affect health during childhood and later life, but treatment choices for younger children are limited.
Wegovy is a medicine made by Novo Nordisk that contains semaglutide and is given by injection. It acts on appetite and has been used to treat obesity in adults and some older children; younger children have not had an approved medicine specifically for obesity.
The trial compared the medicine with a placebo, alongside support for diet and physical activity. Its results may inform future treatment options, while longer-term effects on children’s health and how treatment might continue as they grow remain open questions.